FDA Approves PTSD Device; GLP-1s for ADHD? Probiotics and Geriatric Depression

The FDA cleared Wave Neuroscience’s biomarker-guided neuromodulation system (MeRT) to treat post-traumatic stress disorder (PTSD), the company announced.

Gastrointestinal interoception was disrupted across multiple domains in a study of weight-restored women with anorexia nervosa, with several interoceptive markers tied to relapse risk. (JAMA Psychiatry)

Social media users shared anecdotal reports suggesting GLP-1 drugs may ease symptoms of attention deficit-hyperactivity disorder (ADHD). (New York Post)

Meanwhile, claims data indicated that psychiatrists prescribed roughly 6% of all GLP-1 agents for privately insured U.S. patients from 2018 to 2023. (Journal of Clinical Psychiatry)

A systematic review and meta-analysis showed that psychological and psychosocial interventions had small-to-medium effect sizes on reducing auditory hallucinations in people with schizophrenia spectrum disorders. (JAMA Psychiatry)

Dads can have postpartum depression, too. (Axios)

At-home low-field magnetic stimulation failed to outperform sham on clinician-rated depression in patients with bipolar depression, a randomized study in China found. (Journal of Affective Disorders)

Adding probiotic supplementation to standard care yielded modest improvements in depressive and anxiety symptoms compared with placebo, a trial of adults with geriatric depression showed. (Journal of the American Geriatrics Society)

Psychosis was tied to lower subcortical iron-sensitive MRI values primarily in the substantia nigra, a meta-analysis showed. (American Journal of Psychiatry)

Neumora Therapeutics scrapped development of its investigational depression drug navacaprant after it failed a pair of clinical trials.

An Alzheimer’s disease specialist revealed how she missed early signs of the condition in her father. (STAT)